CStone Pharmaceuticals 2026 Interim Report Summary
Securities Code: 300765 Securities Abbreviation: CStone Pharmaceuticals Announcement No.: 2026-074
CStone Pharmaceuticals
2026 Interim Report Summary
One, Important Notice
This interim report summary is derived from the full interim report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full interim report on the designated media of the China Securities Regulatory Commission.
All directors attended the board meeting to review this report.
Non-standard audit opinion notice
□ Applicable Not applicable
Board of Directors' review of profit distribution plan or capital reserve to increase share capital plan for the reporting period
The company plans not to distribute cash dividends, not to send bonus shares, and not to convert capital reserves into share capital.
Board of Directors' resolution on the profit distribution plan for preferred shares in the reporting period
Two, Company Basic Information
- Company Profile
Stock Abbreviation
Stock Exchange
Shenzhen Stock Exchange
Stock Code
300765
Previous Stock Abbreviation (if any)
Xin Nuo Wei
Contacts and Contact Information
Name
Title
Secretary of the Board
Securities Affairs Representative
Xu Wen
Telephone
0311-67809843
Office Address
No. 62 Zhangju Road, Luancheng District, Shijiazhuang City, Hebei Province
- Key Accounting Data and Financial Indicators
Does the company need to retrospectively adjust or restate previous year's accounting data?
□ Yes No
Revenue (RMB)
Net profit attributable to parent company shareholders (RMB)
Net profit attributable to parent company shareholders after deducting non-recurring gains and losses (RMB)
Net cash flow from operating activities (RMB)
Basic earnings per share (RMB/share)
Diluted earnings per share (RMB/share)
This Report Period
3,240,242,226.11
1,261,185,991.32
1,225,931,718.53
2,776,141,829.90
0.9056
Previous Year Period
1,049,557,677.74
-2,746,143.